An official website of the United States government
Home
Name
Ceplene
Alternate Names
Maxemine
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
None
NSC Number
None
Primary Site
Kidney cancer
leukemia
Histology
None
Remarks
Phase II (kidney) Phase III (AML) Synthetic nucleoside analog. Maxim Pharmaceuticals. Ceplene therapy has been developed to maintain the integrity of pivotal immune cells, in particular T cells and natural killer (NK) cells, in patients with cancer. Ceplene treatment aims at facilitating immune-mediated destruction of cancer cells, including leukemic cells, and also at improving the efficiency of T and NK cell-activating agents such as IL-2.
Coding
This drug should be coded
